2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Metagone Biotech Inc.,

Company Presentations

Friday, July 24 Company Presentations 5–Diagnostics, Device, NPO

Metagone Biotech Inc.,

Company Info

Name /Metagone Biotech Inc.,

Address /3F., No. 11, Ln. 77, Xing-Ai Rd.

Website /www.metagone.com.tw

Presenter

Name /Maggie Lu

Title /General manager

Email /maggie@metagone.com.tw

Telephone /(Work) +886 (2) 27906566 Ext.201

Fax /+886 (2) 27908309

Mobile /0922098205

Company Type

Biotechnology

About the Company

Metagone Biotech is a biotech company based in Taiwan focusing on precision medicine with a particular interest in novel targets.  Our development pipeline span the range of early discovery (i.e. META1) to early clinical stage (i.e. MG-S-2525 and MG-D-1509).

Brief Description of main products or services

We Focus on First-in-class Drugs with Novel Targets.

 

  1. 1509 agnostic antitumor project: completed phase I in TSGH in Taipei, new molecule and novel combination use without safety concern issue. There is particular benefit on NSCLC patients remaining SD in long term. We will get the CSR draft from CRO by 2020. June.  The clinical trials of 1609 have been started to recruite the first patient from 5/27th/2020 in Australia, the whole trials of phase I and II are expected to be completed in 2021 Q3.

  2. 2525 IPF project: new drug completed phase I in TMU,  submitted the CSR report to TFDA and USFDA in this March. DLT increase to highest dose 800mg without any safety issue.  Currently, we are preparing for new indication on CPFE pivotal trial in TMU.

  3. Meta-1 inhibitor project: novel target and pathway on anti-cancer metastasis. Selected good hit, going for lead optimization on nM anti-invasion efficacy which is the best level from literature. Will evaluate efficacy on animal study soon.

Contact Person

Name /Evelyn

Email /evelyn@metagone.com.tw

Phone /+886 (2) 27906566 Ext.215